Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.
Results from a small study suggest that low-dose ketamine could be an effective treatment for children living with ADNP syndrome, otherwise known as Helsmoortel-VanDerAa syndrome.
Biotech company, Mind Medicine Inc, is expanding its drug development pipeline with the launch of a programme to develop R(-)-MDMA for the treatment of social anxiety...
